Current regulatory and market environment for biosimilars in Serbia

Pejović, Gordana; Filipović, Jovan

doi:10.2478/sjph-2014-0011

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of total costs attributed to anti-cancer treatment in recurrent MM was 92% for lenalidomide-based regimens, 90% for bortezomibbased regimens and 54% for thalidomide-based protocols. The higher proportions of drug costs in comparison to other studies [39,40) can be explained by the fact that the pricing of medications in Serbia is based on the European Union recommendations [42], while the unit costs of diagnostic procedures and inpatient care are significantly lower in Eastern Europe.…”

Section: Discussionmentioning

confidence: 75%

Costs of sequential multiple myeloma treatment for elderly transplant-ineligible patients in the Serbian health care system

et al. 2019

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable malignant plasma-cell proliferation manifesting with bone pain, hypercalcemia, anemia, renal insufficiency and malaise [1]. It accounts for approximately 10% of all hematologic malignancies worldwide and it commonly affects the elderly population, and the median age at diagnosis is between 65 and 70 years [2]. The incidence of hematologic malignancies is remarkably lower in Eastern European coun-88 Summary Introduction. Multiple myeloma is an incurable plasma-cell proliferation mainly affecting the elderly population. The aim of this study was to analyze treatment patterns, utilization of health resources and treatment costs of multiple myeloma in the elderly patients ineligible for autologous hematopoietic stem cell transplantation in Serbia. Material and Methods. The analysis of the healthcare costs, from the perspective of the Serbian healthcare system, took into account the costs of medications, diagnostic procedures, inpatient and outpatient care, as well as the costs of drug administration and management of drug adverse effects. Results. Thalidomide based regimens were less costly than bortezomib-based regimens (average per-protocol costs 6,000 € vs. 64,700 €, respectively). The most expensive treatment regimen was lenalidomidedexamethasone (average per-protocol costs 145,200 €). The sequential (four-line therapy) treatment costs varied from 85,800 €, starting with melphalan-prednisone-thalidomide to 153,800 €, starting with melphalan-prednisone-bortezomib. The estimated costs did not significantly differ during variation of the parameters in the sensitivity analysis. Conclusion. The costs of multiple myeloma treatment in the Republic of Serbia are mainly driven by the cost of anti-myeloma drugs. The most expensive treatment sequence was starting with melpha1an-prednisone-bortezomib treatment protocol.

show abstract

Section: Discussionmentioning

confidence: 75%